Katerina Poulopoulou

Ms. Katerina Poulopoulou


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Eleni GavriilakiEleni Gavriilaki
Eleni Gavriilaki
PDPANAGIOTIS DOLGYRAS
PANAGIOTIS DOLGYRAS
SDSotiria Dimou-Mpesikli
Sotiria Dimou-Mpesikli
KPKaterina Poulopoulou
Katerina Poulopoulou
Paschalis EvangelidisPaschalis Evangelidis
Paschalis Evangelidis
ISIoanna Sakellari
Ioanna Sakellari
(1) Background: Autologous, allogeneic hematopoietic cell transplantation (HCT) and other cellular therapies, including CAR T cell and gene therapy, constitute a cornerstone in the management of various benign and malignant hematological disorders. Invasive fungal infections (IFD) remain a significant cause of morbidity and mortality in HCT recipients. Therefore, we investigated the prevalence and risk factors of IFD following HCT and other cellular therapies in an era of novel antifungal prophylaxis. (2) Methods: In this study, we retrospectively enrolled adult HCT recipients who were treated at our JACIE-accredited center according to standard operating procedures over the last decade (2013–2022). (3) Results: 950 patients who received cellular therapies were studied. None of the 19 CAR T cell and neither of the two gene therapy recipients developed IFD whereas 3/456 autologous HCT recipients who suffered from primary refractory/relapsed lymphomas presented with probable IFD. Overall, 11 patients who received allogeneic HCT experienced probable IFD, possible IFD was found in 31/473, and IFD was proven in 10/473. A second IFD episode was present in three patients. Four-year OS was significantly lower in proven compared to probable IFD (p = 0.041) and was independently associated with HCT-CI (p = 0.040) and chronic GVHD (p = 0.045). (4) Conclusions: In this real-world cohort, the prevalence of proven and probable IFD in an era of novel antifungal prophylaxis was found to be relatively low. However, IFDs were associated with poor outcomes for patients who received allogeneic HCT.

15 July 2021 in Journal of Neurosurgical Anesthesiology
Verified
Journal Article
Closed access
GTGeorgia G. Tsaousi
Georgia G. Tsaousi
IPIoakeim Pezikoglou
Ioakeim Pezikoglou
ANAnastasia Nikopoulou
Anastasia Nikopoulou
NFNicolaos G. Foroglou
Nicolaos G. Foroglou
KPKaterina Poulopoulou
Katerina Poulopoulou
DVDimitrios Vasilakos
Dimitrios Vasilakos
Background: Hyperosmolar therapy is the mainstay of treatment to reduce brain bulk and optimize surgical exposure during craniotomy. This study investigated the effect of equiosmolar doses of 7.5% hypertonic saline (HTS) and 20% mannitol on intraoperative cerebral oxygenation and metabolic status, systemic hemodynamics, brain relaxation, markers of cerebral injury, and perioperative craniotomy outcomes. Methods: A total of 51 patients undergoing elective supratentorial craniotomy were randomly assigned to receive 7.5% HTS (2 mL/kg) or 20% mannitol (4.6 mL/kg) at scalp incision. Intraoperative arterial and jugular bulb blood samples were collected at predefined time intervals for assessment of various indices of cerebral oxygenation; multiple hemodynamic variables were concomitantly recorded. S100B protein and neuron-specific enolase levels were determined at baseline, and at 6 and 12 hours after surgery for assessment of neuronal injury. Brain relaxation and perioperative outcomes were also assessed. Results: Demographic and intraoperative data, brain relaxation score, and perioperative outcomes were comparable between groups. Jugular bulb oxygen saturation and partial pressure of oxygen, arterial-jugular oxygen and carbon dioxide differences, and brain oxygen extraction ratio were favorably affected by 7.5% HTS up to 240 minutes postinfusion (P<0.05), whereas mannitol was associated with only a short-lived (up to 15 min) improvement of these indices (P<0.05). The changes in cerebral oxygenation corresponded to transient expansion of intravascular volume and improvements of cardiovascular performance. Increases in S100B and neuron-specific enolase levels at 6 and 12 hours after surgery (P<0.0001) were comparable between groups. Conclusions: The conclusion is that 7.5% HTS has a more beneficial effect on cerebral oxygenation than an equiosmolar dose of 20% mannitol during supratentorial craniotomy, yet no clear-cut clinical superiority of either solution could be demonstrated.

29 March 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
MDMaria Drogari-Apiranthitou
Maria Drogari-Apiranthitou
ASAnna Skiada
Anna Skiada
IPIoannis G. Panayiotides
Ioannis G. Panayiotides
Timoleon-Achilleas VyzantiadisTimoleon-Achilleas Vyzantiadis
Timoleon-Achilleas Vyzantiadis
KPKaterina Poulopoulou
Katerina Poulopoulou
ΓΠΓεώργιος Λ. Πετρίκκος
Γεώργιος Λ. Πετρίκκος
Mucormycosis has emerged as a group of severe infections mainly in immunocompromised patients. We analysed the epidemiology of mucormycosis in Greece in a multicentre, nationwide prospective survey of patients of all ages, during 2005–2022. A total of 108 cases were recorded. The annual incidence declined after 2009 and appeared stable thereafter, at 0.54 cases/million population. The most common forms were rhinocerebral (51.8%), cutaneous (32.4%), and pulmonary (11.1%). Main underlying conditions were haematologic malignancy/neutropenia (29.9%), haematopoietic stem cell transplantation (4.7%), diabetes mellitus (DM) (15.9%), other immunodeficiencies (23.4%), while 22.4% of cases involved immunocompetent individuals with cutaneous/soft-tissue infections after motor vehicle accident, surgical/iatrogenic trauma, burns, and injuries associated with natural disasters. Additionally, DM or steroid-induced DM was reported as a comorbidity in 21.5% of cases with various main conditions. Rhizopus (mostly R. arrhizus) predominated (67.1%), followed by Lichtheimia (8.5%) and Mucor (6.1%). Antifungal treatment consisted mainly of liposomal amphotericin B (86.3%), median dose 7 mg/kg/day, range 3–10 mg/kg/day, with or without posaconazole. Crude mortality was 62.8% during 2005–2008 but decreased significantly after 2009, at 34.9% (p = 0.02), with four times fewer haematological cases, fewer iatrogenic infections, and fewer cases with advanced rhinocerebral form. The increased DM prevalence should alert clinicians for timely diagnosis of mucormycosis in this patient population.

14 June 2024 in Medical Mycology
Verified
Journal Article
Open access
PDF file
KPKaterina Poulopoulou
Katerina Poulopoulou
ASAnna Sidiropoulou
Anna Sidiropoulou
TSTheopisti Sarmourli
Theopisti Sarmourli
EZEvaggelia Zachrou
Evaggelia Zachrou
CMChrysi Michailidou
Chrysi Michailidou
Timoleon-Achilleas VyzantiadisTimoleon-Achilleas Vyzantiadis
Timoleon-Achilleas Vyzantiadis
Candida auris is an emerging fungal pathogen associated with multi-drug resistance rates and widespread outbreaks in hospitals and healthcare units worldwide. Sequencing studies have revealed that different clonal lineages of the fungus seem to be prevalent among distinct geographical sites. The first case of C. auris in Northern Greece was reported in Thessaloniki in October 2022, almost 2 years after the first isolation in Greece (Athens 2019). The Mycology Laboratory of the Medical School of Aristotle University of Thessaloniki stands as the reference laboratory for fungal diseases in Northern Greece and a meticulous search for the yeast, in plenty of suspicious samples, has been run since 2019 in the Lab as well as a retrospective analysis of all its yeasts’ collection, back to 2008, with negative results for the presence of C. auris. Here, are presented the findings concerning the outbreak and surveillance of C. auris in Northern Greece, mainly the region of Thessaloniki and the broader area of Macedonia, from October 2022 until August 2023. The isolates from Northern Greece continue to fall in Clade I and present with an almost equal and stable sensitivity profile until now. The study concerns the outbreak of Candida auris in Northern Greece since October 2022 and the effort for surveillance and epidemiological monitoring. All isolates continue to fall in Clade I and present with an almost equal and stable sensitivity profile till now.

5 January 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
PSPanagiotis Dimitrios Siasios
Panagiotis Dimitrios Siasios
KAKostoula Arvaniti
Kostoula Arvaniti
EZEvangelia Zachrou
Evangelia Zachrou
KPKaterina Poulopoulou
Katerina Poulopoulou
PPPinelopi Pisanidou
Pinelopi Pisanidou
Timoleon-Achilleas VyzantiadisTimoleon-Achilleas Vyzantiadis
Timoleon-Achilleas Vyzantiadis
Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) has emerged as an important complication among patients with acute respiratory failure due to SARS-CoV-2 infection. Almost 2.5 years since the start of the COVID-19 pandemic, it continues to raise concerns as an extra factor that contributes to increased mortality, which is mostly because its diagnosis and management remain challenging. The present study utilises the cases of forty-three patients hospitalised between August 2020 and February 2022 whose information was gathered from ten ICUs and special care units based in northern Greece. The main aim was to describe the gained experience in diagnosing CAPA, according to the implementation of the main existing diagnostic consensus criteria and definitions, and present the different classification of the clinical cases due to the alternative algorithms.